New radioactive tracer tested for cancer imaging in tiny early trial

NCT ID NCT06463782

Completed Diagnosis Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already completed, but it is too small and early to draw any conclusions about diagnosing or treating cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-LNC1007 injection (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a new imaging method to help detect or monitor solid tumors more precisely.
What could go wrong: This is a very early, small trial (8 people) focused only on safety and imaging properties, not on treating cancer. It may not lead to any diagnostic or therapeutic benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PATIENTS HEALTHY VOLUNTEERS

Contacts and locations

Locations

Clinical Imaging Research Centre (CIRC) ；National University of Singapore.

Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.